SciBase Holding AB (OSTO:SCIB) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SCIB SciBase Holding AB OSTO:SCIB
43 GF Score
Price kr35.20
GF Value kr21.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB Net Loan?

Net Loan only applies to banks and insurance companies.

OSTO:SCIB
43GF Score
SciBase Holding AB OSTO:SCIB
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of kr35.20 is trading 62% above its estimated GF Value™ of kr21.73. GuruFocus considers SciBase Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:SCIB:

  • Net Loan:
  • GF Value™: kr21.73 vs. price of kr35.20 (62% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SciBase Holding AB Business Description

Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
43GF Score

Get the complete analysis for OSTO:SCIB

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr35.20
Price
kr21.73
GF Value